Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-221 in IDH2 Mutated Myelodysplastic Syndrome
NCT03744390Phase 2Active, not recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Overall hematological response at 6 months. Started Apr 2019; status: active, not recruiting.
02
Drugs
enasidenib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03744390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744390.